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SObjectives: Submucosal esophageal cancers (pT1b) are considered superficial, implying good survival. How-
ever, some are advanced, metastasizing to regional lymph nodes. Interplay of cancer characteristics and lym-
phatic anatomy may create a watershed, demarcating low-risk from high-risk cancers. Therefore, we
characterized submucosal cancers according to depth of invasion and identified those with high likelihood of
lymph node metastases and poor survival.
Methods: From 1983 to 2010, 120 patients underwent esophagectomy for submucosal cancers at Cleveland
Clinic. Correlations were sought among cancer characteristics (location, dimensions, histopathologic cell
type, histologic grade, and lymphovascular invasion [LVI]), and their associations with lymph node metastasis
were identified by logistic regression. Associations with mortality were identified by Cox regression.
Results: As submucosal invasion increased, cancer length (P<.001), width (P<.001), area (P<.001), LVI
(P ¼ .007), and grade (P ¼ .05) increased. Invasion of the deep submucosa (P<.001) and LVI (P ¼ .06) pre-
dicted lymph node metastases: 45% (23/51) of deep versus 10% (3/29) of middle-third and 7.5% (3/40) of
inner-third cancers had lymph node metastases, as did 46% (12/26) with LVI versus 18% (17/94) without. Older
age and lymph node metastases predicted worse 5-year survival: 94% for younger pN0 patients, 62% for older
pN0 patients, and 36% for pN1-2 patients regardless of age.
Conclusions: Submucosal cancer characteristics and lymphatic anatomy create a watershed for regional lymph
nodemetastases in the deep submucosa. This previously unrecognized divide distinguishes superficial submucosal
cancers with good survival from deep submucosal cancers with poor survival. Aggressive therapy of more super-
ficial cancers is critical before submucosal invasion occurs. (J Thorac Cardiovasc Surg 2011;142:1403-11)Supplemental material is available online.
Submucosal esophageal cancers (pT1b) are considered su-
perficial cancers, implying early cancer with good survival.
However, some metastasize to regional lymph nodes and
behave like advanced cancers.1 Recently discovered nonho-
mogeneous esophageal lymphatic anatomy in the mucosa
and submucosa2,3 (Figure 1), coupled with evolving cancer
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The Journal of Thoracic and Carsharply distinguishes submucosal cancers with good sur-
vival from those with poor survival. Therefore, we charac-
terized submucosal cancers according to depth of invasion
and identified those with high likelihood of lymph node me-
tastases and poor survival.
PATIENTS AND METHODS
Patients
From January 1983 to January 2010, 1296 patients underwent esopha-
gectomy for cancer at Cleveland Clinic. Of these, 120 had a pathologic di-
agnosis of adenocarcinoma or squamous cell carcinoma invading the
submucosa but not beyond (pT1b). All had esophagectomy alone without
induction therapy (Table 1). The esophagectomy database used for this
study was approved for use in research by the Institutional Review Board
of Cleveland Clinic, with patient consent waived.
Cancer Characteristics
Cancer location and Barrett length were measured at endoscopy. Cancer
dimensions were measured from the resection specimen. cT was deter-
mined by endoscopic ultrasound (n ¼ 105) and biopsy (n ¼ 15). Depth
of cancer invasion within the submucosa (pT1b) was classified visually
as inner (SM1), middle (SM2), or deep (SM3) thirds. Lymphovascular in-
vasion was histologically identified by invasion of endothelium-lined
spaces by cancer. Lymph node status was determined from final pathologic
analysis using staging criteria from the seventh edition of the American
Joint Committee on Cancer Staging Manual.5
End Point and Follow-up
The end point was all-cause mortality. Cross-sectional systematic
follow-up of patients was complete in 115 (96%) and partial indiovascular Surgery c Volume 142, Number 6 1403
FIGURE 1. Cross-section of esophageal wall and lymphatics. A, Normal esophagus demonstrating lymphatic anatomy. B, Cancer invasion into inner, mid-
dle, and deep submucosa.
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S5 (4.2%). Median follow-up of living patients was 4.4 years; 25% of sur-
vivors were followed up for 8 years and 10% for more than 11 years.
Submucosal Cancer Characteristics
Binary variables were compared according to depth of invasion using
the Cochran-Armitage test; continuous variables were compared using
the Jonckheere-Terpstra test; and ordinal variables were compared using
the Cochran-Mantel-Haenszel correlation test.
Lymph Node Metastasis
Owing to the small number of pN2 patients, lymph node metastases
were analyzed as any (pNþ) versus none (pN0). Logistic regression analysis1404 The Journal of Thoracic and Cardiovascular Surwas used to assess association of individual factors with lymph node me-
tastasis (Appendix 1). Results are summarized as univariable odds ratios,
68% confidence interval for the odds ratios, and corresponding P value.
Multivariable analysis used variables listed in Appendix 1 and used bag-
ging for variable selection.6 In brief, 1000 bootstrap samples of size 120
were selected with replacement from the study data. Stepwise logistic re-
gression models were obtained for each with an entry criterion of P 
.10 and retention criterion of P  .05. The percentage of times each factor
appeared in a stepwise model was tabulated. Variables appearing in more
than 50% of models were considered reliable. Separate analysis was
made of specific interactions of cancer size (depth, length, width, and
area) with lymph node metastasis.gery c December 2011
TABLE 1. Patient, cancer, and treatment characteristics
Characteristic No. of patients (%)
Demographics
Men 102 (85)
Race
White 116 (97)
African American 3 (2.5)
Other 1 (0.8)
Age at operation (y), mean  SD 64  10
Cancer characteristics
Location
Upper esophagus 1 (0.8)
Middle esophagus 5 (4.2)
Lower esophagus 114 (95)
Barrett length (cm) 0/3/9*
cT
cTx 15 (12)
cTis 5 (4.2)
cT1 50 (42)
cT2 38 (32)
cT3 11 (9.2)
cT4 1 (0.8)
pT1b
Inner 40 (33)
Middle 29 (24)
Deep 51 (42)
Esophagectomy
Transhiatal 46 (38)
Thoracotomy 74 (62)
SD, Standard deviation. *The 15th, 50th, and 85th percentiles.
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Nonparametric survival estimates were obtained using the Kaplan-
Meier method. Stratified estimates were compared with the log–rank
test. Cox proportional hazards regression was used to assess individual as-
sociations with survival. Results are summarized as univariable hazard ra-
tios, 68% confidence interval for the hazard ratios, and P values.
Multivariable analysis used variables in Appendix 1 plus number of nodes
resected and pN0 versus pNþfor variable selection as described previously.
Exploratory recursive partitioning analysis was used to illustrate the rela-
tion of age and lymph node metastasis to survival.7
Presentation
Continuous variables are summarized as mean  1 standard deviation
for normally distributed variables and as equivalent median, 15th, and
85th percentiles for skewed distribution. Categorical variables are summa-
rized as frequency and percentage. Survival estimates are accompanied by
68% confidence limits equivalent to  1 standard error.RESULTS
Submucosal Cancer Characteristics and Surgery
As submucosal invasion increased, cancer length
(P < .001), cancer width (P < .001), cancer area (P <
.001), histologic grade (P ¼ .05), lymphovascular invasion
(P ¼ .007), number of positive nodes (P<.001), and path-
ologic N classification (P < .001) increased (Table 2,
Figure 2). Total number of nodes sampled increased
(P ¼ .02), and more thoracotomies were performedThe Journal of Thoracic and Car(P ¼ .05) with increasing depth of invasion (Table 2). Me-
dian number of lymph nodes resected was 10 (15th and 85th
percentiles, 3 and 19) for transhiatal esophagectomy and 18
(15th and 85th percentiles, 6 and 32) for thoracotomy. His-
topathologic cell type was not associated with cancer char-
acteristics (Table E1).
Risk Factors for Lymph Node Metastases
Prevalence of lymph node metastases was similar for
men and women, age, length of Barrett esophagus, and his-
topathologic cell type (Table 3). However, cancer dimen-
sions, lymphovascular invasion, and histologic grade were
individually associated with greater occurrence of lymph
node metastases (Table 4). Owing to the strong association
of depth of invasion with cancer characteristics, multivari-
able analysis identified only invasion of the deep submu-
cosa (P< .001) as an independent risk factor: 45% (23/
51) of deep cancers versus 10% (3/29) of middle-third
and 7.5% (3/40) of inner-third cancers had lymph node me-
tastases. Lymphovascular invasion was possibly (P ¼ .06)
an independent risk factor. Of 26 patients with lymphovas-
cular invasion, 12 (46%) had lymph node metastases; of 94
without lymphovascular invasion, 17 (18%) had lymph
node metastases (P ¼ .003). Of 5 patients with a G1 cancer
confined to the inner submucosa without lymphovascular
invasion, none had lymph node metastases.
Prognostic Factors for Survival
Survival was 90%, 61%, and 46% at 1, 5, and 10 years
after esophagectomy, respectively. For patients with pN0
cancers, survival was 92%, 70%, and 53% at these inter-
vals, but 86%, 36%, and 24% for patients with pN1-2 can-
cers (Figure 3; P < .001). No tumor dimension was
individually associated with survival because of the over-
whelming effect of lymph node metastasis on mortality
(Table 5). Multivariable analysis also identified older age
at esophagectomy as a risk factor; however, recursive parti-
tioning indicated that lymph node metastasis also over-
whelms the effect of age (Figure 4). Thus, 5-year survival
was 94% for younger pN0 patients and 62% for older
ones, but 36% for pN1-2 patients regardless of age.
DISCUSSION
Principal Findings
This study demonstrates that submucosal cancer is not
a superficial cancer. For submucosal esophageal cancer
(pT1b), both deep submucosal invasion and possibly lym-
phovascular invasion predicted regional lymph node metas-
tases. Only regional lymph node metastasis was associated
with mortality.
Lymphatic anatomy. D2-40 immunohistochemical stain-
ing differentiates lymphatic endothelium from capillary en-
dothelium, permitting better understanding of the lymphatic
anatomy of the esophageal wall.2,3 Lymphatics arediovascular Surgery c Volume 142, Number 6 1405
TABLE 2. Cancer characteristics by depth of invasion
Variable/response
Inner (n ¼ 40) Middle (n ¼ 29) Deep (n ¼ 51)
P
No. (%) or 15th/50th/85th
percentiles
No. (%) or 15th/50th/85th
percentiles
No. (%) or 15th/50th/85th
percentiles
Greatest cancer length (cm)* 0/1.2/2.7 1.0/1.9/3.0 1.5/2.5/4.0 <.001
Greatest cancer width (cm)* 0/0.8/1.7 0.5/1.1/2.0 0.8/1.5/3.0 <.001
Cancer area (cm2)* 0/1.0/4.0 0.2/2.2/4.0 1.1/3.4/12 <.001
Histopathologic type .7
Adenocarcinoma 35 (88) 26 (90) 46 (90)
Squamous cell carcinoma 5 (12) 3 (10) 5 (9.8)
Histologic grade .05
G1 5 (12) 4 (14) 7 (14)
G2 24 (60) 16 (55) 17 (33)
G3 11 (28) 9 (31) 27 (53)
Lymphovascular invasion 4 (10) 5 (17) 17 (33) .007
No. of positive lymph nodes <.001
0 37 (92) 26 (90) 28 (55)
1 3 (7.5) 1 (3.4) 16 (31)
2 0 (0) 0 (0) 4 (7.8)
3 0 (0) 0 (0) 2 (3.9)
4 0 (0) 0 (0) 1 (2.0)
5 0 (0) 2 (6.9) 0 (0)
Pathologic classification <.001
pN0 37 (92) 26 (90) 28 (55)
pN1 3 (7.5) 1 (3.4) 20 (39)
pN2 0 (0) 2 (6.9) 3 (5.9)
Extracapsular lymph node involvement 0/3 0/3 5/21y .2
Total number of lymph nodes sampled 4/10/22 6/16/32 5/15/29 .02
Surgical approach: thoracotomy 20 (50) 18 (62) 36 (71) .05
*Inner, n ¼ 39; middle, n ¼ 28; deep, n ¼ 50. yData available.
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Sabundant in the lamina propria of the mucosa. These
lymphatics have no direct connections with regional
lymphatics or thoracic duct, and they drain through the
mural lymphatic plexus to reach regional lymph nodes
(see Figure 1, A). Lymphatics are more sporadic in the sub-
mucosa and muscularis propria. In the submucosa they ap-
pear to be concentrated in the deep submucosa and have
direct connections to more central lymphatic channels.2
Submucosal cancer characteristics. More deeply invad-
ing esophageal cancers are larger.8 Our study shows that
as submucosal cancers invade deeper, they grow centrifu-
gally as well, with cancer surface area tripling as invasion
proceeds from superficial to deep submucosa. Deeper sub-
mucosal invasion is associated with more undifferentiated
cancer growth (more G2 and G3 cancers) for both esopha-
geal4 and colorectal cancers.9 G1 cancers were uncommon
and equally distributed through the submucosa, G2 cancers
predominated in the more superficial submucosa, and deep
submucosal cancers were most likely to be G3 cancers.
It may be that cancers dedifferentiate as they invade; how-
ever, another explanation is that more aggressive cancers
are more likely to be deeply invasive on presentation. Re-
gardless, grade, a crude measure of cancer biology, is linked
with cancer size and invasion.1406 The Journal of Thoracic and Cardiovascular SurRegional lymph node metastasis. Reported to be rare in
mucosal cancers,10 regional lymph node metastasis is sur-
prisingly common in submucosal cancers, and the likeli-
hood of this increases exponentially with deeper
submucosal invasion.11 This conforms with recent immuno-
histochemical mapping of the esophageal lymphatics and
characteristics of submucosal cancers.2,3 We and many
others3,12-17 have found that lymphovascular invasion is
the initial step toward regional lymph node metastasis.
Similar to our findings, deeper submucosal invasion also
has been found to be associated with increasing regional
lymph node metastases.12,14,18-22
As a cancer grows centrifugally, it encounters more mu-
cosal lymphatics, increasing the possibility of lymphatic in-
vasion and metastases to regional lymph nodes. In addition,
with deeper submucosal invasion there is increased likeli-
hood for invasion of lymphatics with more direct connec-
tions to regional lymph nodes. Therefore, the growth
pattern, both centrifugal and deep, coupled with the unique
lymphatic anatomy of the esophagus, produces a watershed
in the deep submucosa, the invasion of which results in
a high risk of regional lymph metastases. Nearly one half
of patients with invasion of the deep submucosa have re-
gional lymph node metastases.gery c December 2011
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FIGURE 2. Histograms demonstrating relationship of cancer characteris-
tics to depth of submucosal cancer invasion. Adeno, adenocarcinoma; LVI,
lymphovascular invasion; SCC, squamous cell carcinoma.
TABLE 3. Prevalence of lymph node metastases according to patient
and cancer characteristics
Characteristic
No. of
Patients
No. with lymph node
metastases (%) P
Demographics
Sex .8
Men 102 25 (24)
Women 18 4 (22)
Age at operation (y) .7
55 31 10 (32)
56-65 31 7 (23)
66-71 26 3 (12)
>71 32 9 (28)
Cancer characteristics
Barrett length (cm) .4
0 34 6 (18)
0.5-2.5 24 7 (29)
3-6 32 9 (28)
7-14 29 7 (24)
Cancer length (cm)* .02
0.0-0.9 21 2 (9.5)
1.0-1.9 33 6 (18)
2.0-2.9 37 12 (32)
3.0-8.0 26 9 (35)
Cancer width (cm) .01
0-0.5 29 4 (14)
0.6-1.0 33 7 (21)
1.1-1.9 30 7 (23)
2.0-5.5 25 11 (44)
Cancer area (cm2) .02
0-0.5 29 4 (14)
0.6-1.9 26 5 (19)
2.0-4.9 34 8 (24)
5.0-40 28 12 (43)
pT1b <.001
Inner 40 3 (7.5)
Middle 29 3 (10)
Deep 51 23 (45)
Histopathologic cell type .9
Adenocarcinoma 107 26 (24)
Squamous cell carcinoma 13 3 (23)
Histologic grade .09
G1 16 1 (6.2)
G2 57 14 (25)
G3 47 14 (30)
Lymphovascular invasion .004
Yes 26 12 (46)
No 94 17 (18)
Esophagectomy .01
Transhiatal 46 5 (11)
Thoracotomy 74 24 (32)
*n ¼ 117.
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ated with deeper submucosal invasion. We found that no pa-
tient with superficial invasion had more than 1 regional
lymph node metastasis. However, 7% of cancers with inva-
sion of the middle third and 14% of deep submucosal can-
cers had 2 or more regional lymph node metastases.
Extracapsular lymph node involvement was observed only
with deep submucosal invasion.
Survival. Presence of regional lymph node metastasis has
an overwhelming negative effect on survival. Curiously, no
other examined variable was prognostic, because of the
strong association of cancer characteristics with lymphatic
metastases. The association of deep submucosal invasionThe Journal of Thoracic and Carwith regional nodal metastasis and its effect on survival em-
phasizes how this lymphatic watershed affects survival.
Increasing patient age was the only other factor associ-
ated with increased mortality. Although older patients
die sooner than younger patients, the present analysisdiovascular Surgery c Volume 142, Number 6 1407
TABLE 4. Risk factors for lymph node metastasis: Logistic regression
analysis
Characteristic
Odds
ratio* 68% CI P
Reliability
(%)y
Demographics
Male/female 1.14 0.62-2.09 .8 2.2
Age at operation (y)
Per 10-y increase 0.91 0.74-1.13 .7 6.2
Cancer characteristics
Barrett lengthz
Per 1-cm increase 1.04 0.99-1.10 .4 9.4
Cancer dimensions
Length (cm)x
Per 1-cm increase 1.42 1.23-1.63 .02 8.5
Width (cm)x
Per 1-cm increase 1.68 1.37-2.04 .01 9.9
Area (cm2)x
Per 1-cm2 increase 1.09 1.05-1.13 .02 6.9
pT1b width
Middle/inner 1.42 0.61-3.33 .7 1.9
Deep/inner 10.13 5.24-19.59 .001 94
Histopathologic cell type
Adenocarcinoma/
squamous cell
carcinoma
1.07 0.54-2.14 .9 0.7
Histologic grade
G2/G1 4.88 1.67-14.26 .14 17
G3/G1 6.36 2.17-18.64 .09 1.7
G3/G1-2 1.64 1.07-2.52 .2 1.7
G2-3/G1 5.53 1.93-15.80 .11 13
Lymphovascular invasion
Yes/no 3.88 2.42-6.23 .004 35
CI, Confidence interval. *Odds ratio for univariable analyses. yPercent of times factor
appeared in 1000 bootstrapped multivariable models. zn ¼ 119. xn ¼ 117.
TABLE 5. Association of individual variables with mortality by Cox
proportional hazards analysis
Characteristic
Hazard
ratio* 68% CI P
Reliability
(%)y
Demographics
Male/female 1.28 0.85-1.92 .6 16
Age at operation (y)
Per 10-y increase 1.38 1.19-1.61 .03 48
Cancer characteristics
Barrett lengthz
Per 1-cm increase 0.98 0.95-1.02 .7 4.9
Cancer dimensions
Length (cm)x
Per 1-cm increase 0.98 0.90-1.08 .8 9.2
Width (cm)x
Per 1-cm increase 1.01 0.89-1.16 .9 8.8
Area (cm2)x
Per 1-cm2 increase 1.00 0.98-1.02 .9 6.7
pT1b
Middle/inner 1.04 0.71-1.51 .9 12
Deep/inner 1.33 0.96-1.84 .4 12
Histopathologic cell type
Adenocarcinoma/
squamous cell
carcinoma
0.65 0.45-0.94 .2 28
Histologic grade
G2/G1 1.20 0.73-1.97 .7 6.0
G3/G1 1.72 1.05-2.81 .3 7.4
G3/G1-2 1.49 1.12-1.97 .16 7.4
G2-3/G1 1.43 0.89-2.29 .4 2.2
Lymphovascular invasion
Yes/No 1.38 0.95-2.01 .4 19
pN
pN1/pN0 2.94 2.12-4.07 .001 88
pN2/pN0 3.56 1.92-6.60 .04 69
CI, Confidence interval. *Hazard ratio for univariable analyses. yPercent of times fac-
tor appeared in 1000 bootstrapped multivariable models. zn ¼ 119. xn ¼ 117.
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derly with submucosal cancers. In these cancers with ex-
pected good survival, compared with the averageFIGURE 3. Survival after esophagectomy by pN classification. Vertical
bars represent  1 standard error, and legend shows number of patients
at risk. Tick marks indicate censored patients.
1408 The Journal of Thoracic and Cardiovascular Suresophageal cancer, the presence of submucosal invasion,
particularly limited to the inner and middle thirds, does
not cause overwhelming mortality, and the influence of
age on survival can be appreciated.STRENGTHS AND LIMITATIONS
This is a single-institution experience covering more than
20 years. It represents a highly selected referral population.
It is a surgical series; therefore, patients with submucosal
cancers that are not medically operable and those with dis-
tant metastases (none of whom we are aware) are not repre-
sented. This series may underestimate regional lymph node
metastases.23 Failure to identify regional lymph node me-
tastases may be a reflection of extent of lymphadenectomy,
which increased with time, influenced by change in surgical
approach to thoracotomy.
Submucosal cancers are uncommon, but this is a large pa-
tient volume of long-term data necessary to providegery c December 2011
FIGURE 4. Survival after esophagectomy by age and pN classification.
Depiction is as in Figure 3.
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Sstrength to identify associations. Although large compared
with other reports, it still may be too small to detect weaker
associations.
CONCLUSIONS AND RECOMMENDATIONS
The submucosa is the critical anatomic layer of the
esophagus within which there are major lymphatic connec-
tions. Cancers invading the submucosa have unique growth
features. The interplay of these produces the watershed ef-
fect of deep submucosal invasion. Increasing depth of sub-
mucosal invasion is associated with a disproportionately
increasing occurrence of regional lymph node metastases,
leading to decreasing survival.
The potential difficulty in accurately and repeatedly de-
termining depth of submucosal invasion clinically, the
high likelihood of regional lymph node metastases for any
submucosal cancer (range, 10%-50%), and the rarity of
a well-differentiated (G1) inner submucosal cancer without
lymphovascular invasion requires complete removal of
a submucosal esophageal cancer with its regional lymph no-
des. Aggressive therapy of more superficial cancers is crit-
ical before submucosal invasion occurs.
Because the submucosa lymphatic anatomy is nonhomo-
geneous, the boundary for a superficial cancer is not at the
border of the submucosa and muscularis propria. A submu-
cosal cancer is not a superficial cancer. This term should be
limited to mucosal cancer.
We thank Janet Rice for assistance with manuscript preparation
and Tess Parry for editorial help.
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APPENDIX 1. VARIABLES ASSESSED IN DATA
ANALYSES
Demographics: Sex, age.
Cancer characteristics: Barrett length, cancer dimensions
(length, width, area, volume), histopathologic cell type,diovascular Surgery c Volume 142, Number 6 1409
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Shistologic grade, lymphovascular invasion, number of pos-
itive lymph nodes, pathologic N-classification, depth of
cancer invasion.Discussion
Dr David R. Jones (Charlottesville, Va). I thank the Associa-
tion for the opportunity to discuss this fine paper. I have no disclo-
sures related to the discussion. It is a pleasure to review and then
discuss yet another paper from Dr Raja and colleagues from the
Cleveland Clinic Foundation. As we are all aware, the Cleveland
Clinic and, in particular, the senior author of this paper, Dr Rice,
have been leaders in the surgical treatment of esophageal cancer,
and this presentation certainly adds value to our understanding
of the pathobiology of the disease. Dr Raja, I have 3 questions
for you, and I will ask them 1 at a time.
First, given that the submucosal layer is measured to be roughly
half a millimeter, how difficult is it in measuring thewidth and sub-
sequent depth of mucosal invasion by the pathologists? It strikes
me that this may be quite subjective. What are your comments
with respect to this issue?
Dr Raja. Our pathologists tell us the submucosa varies from
200 to 1000 mm. Although there is a degree of subjectivity, di-
viding it into thirds has not been a problem for our and other pa-
thologists. Submucosal cancers have a defined prevalence of
regional lymph node metastases, and even invasion of the inner
third of the submucosa is associated with meaningful lymphatic
metastases.
Dr Jones. Second, how does the information that you have pre-
sented affect your clinical decision making when your initial endo-
scopic ultrasound report classifies the T stage as T1a or T1b?
Would you now advocate a transthoracic approach and perhaps
a more aggressive mediastinal node dissection versus, for instance,
a transhiatal?
Dr Raja.We rely on endoscopic ultrasound to identify submu-
cosal (T1b) cancer. In patients in whom the clinical differentiation
of intramucosal from submucosal cancer is uncertain, we use en-
doscopic mucosal resection and pathologic review of that speci-
men. We believe that endoscopic therapies should be reserved
for no more than intramucosal cancer.
We have previously published that a minimum of 10 lymph
nodes need to be resected and examined to maximize 5-year
survival in patients with T1 cancer.* This frequently requires
a transthoracic approach. This study has taught us that long, circum-
ferential, poorly differentiated cancers and those cancers with lym-
phovascular invasion are more likely to have deep submucosal
invasion and thus a very high rate of regional lymph nodemetastases.
Today these findings would dictate a transthoracic approach. In our
study, 60% of patients had a transthoracic approach and 40% had
a transhiatal approach, and there was no survival difference.
Dr Jones. Thank you. You actually addressed my last question
with how this relates to endoscopic mucosal resection.*Rizk N, Venkatraman E, Park B, Flores R, Bains MS, Rusch V; American Joint
Committee on Cancer staging system. The prognostic importance of the number
of involved lymph nodes in esophageal cancer: implications for revisions of the
American Joint Committee on Cancer staging system. J Thorac Cardiovasc
Surg. 2006;132:1374-81.
1410 The Journal of Thoracic and Cardiovascular SurDr Hiran Fernando (Boston, Mass). Dr Raja, that was an
excellent presentation. You showed a couple of slides that cor-
related depth of invasion with grade and with length and with
the area of the tumor that you see. Those would be much easier
end points to measure preoperatively if you were contemplat-
ing doing a submucosal resection or an endoscopic resection
for these patients. Do you know what the outcomes are for
those 3 things—the grade, the length, and the area—related
to things such as survival and incidence of occult nodal
disease?
Dr Raja. By univariable analysis, all of these factors were
found to be significant for regional lymph node metastases. Be-
cause of the interplay among these factors, multivariable analysis
identified only one important predictor of regional lymph node
metastases: deep submucosal invasion. Subsequent survival was
related to the presence of regional lymph node metastases. Al-
though one could use these other factors that were significant in
univariable analysis, the most reliable factor for clinical decision
making is deep submucosal invasion.
Dr Wayne L. Hofstetter (Houston, Tex). I congratulate you on
a nice presentation. I have a couple of questions. You mentioned
that the D2-40 marker was used. Did you go back retrospectively
and look for submucosal invasion with the D2-40 marker or immu-
nohistochemistry or, secondarily, on the older specimens, did you
rereview for lymphovascular invasion?
Dr Raja.We did not use the D2-40 marker. Our pathologists re-
viewed all hematoxylin and eosin slides for lymphovascular
invasion.
Dr Hofstetter. When we rereviewed our slides with a second
pathologist, we found that we upstaged to lymphovascular inva-
sion about 10% of the time, so that was interesting to us.
The second question was regarding patients that manifested su-
perficial submucosal invasion. You had 8% that were lymph node
positive. How many of those patients were lymphovascular inva-
sion positive or lymphovascular invasion negative? This informa-
tion has implications in terms of the applicability of endoscopic
mucosal resection.
Dr Raja. Forty-six percent of patients with lymphovascular in-
vasion had regional lymph node metastases as opposed to 18%
without regional lymph node metastases. For patients with only in-
ner submucosal invasion, lymphovascular invasion was present in
none with lymph node metastasis and 11% without lymph node
metastasis, a reflection of 8% prevalence of regional lymph node
metastasis.
Dr Hofstetter. Finally, in terms of the patients that were T1b,
N1, you revealed that overall survival was 36% at 5 years. I am
not surprised that there was no difference in your approach surgi-
cally from transthoracic to transhiatal, because this is a marker, as
you are indicating, of watershed or systemic disease. Because we
are having such poor outcomes with these T1b, N1 patients, are
you considering neoadjuvant therapy for this group of patients if
they could be identified preoperatively?
Dr Raja.When regional lymph node metastasis is found at re-
section, we offer our patients postoperative adjuvant therapy. Pre-
operatively, if regional lymph node metastasis is detected in
patients with submucosal cancer, neoadjuvant therapy is pre-
scribed. For the majority of patients with submucosal cancer, neo-
adjuvant therapy is excessive.gery c December 2011
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SDr Toni Lerut (Leuven, Belgium). Dr Raja, thank you very
much and congratulations for an original study. We have done
a similar study on a similar number of patients. We found
a much higher incidence of positive lymph nodes in the more su-
perficial layer, as well as in the deeper layers, than displayed by the
data that you showed. This was true particularly in squamous but
also in adenocarcinoma, up to 33% positive nodes for the superfi-
cial layer. You said that you had 40% transhiatal esophagectomies
and 60% transthoracic esophagectomies. I suspect that you have
done proportionally more transhiatal resections for the more super-
ficial carcinomas that also happened to be smaller carcinomas. We
all know that the more nodes you remove, the greater the chance
for positive nodes. Could you give us more insight in that respect?
What was the number of removed nodes?
Dr Raja. The median number of lymph nodes resected was 14
(10 with the transhiatal approach and 18 with the transthoracic ap-
proach). A transthoracic approach was used in 50% of patients
with inner cancers, 62% with middle cancers, and 71% with
deep cancers. Eleven percent had squamous cell cancer, too few
to analyze. Your supposition that transhiatal resection was used
less frequently for cancer with deeper invasion is correct. There-
fore, it is possible that resecting more regional lymph nodes for
less invasive cancer may reveal a higher prevalence of lymph
node metastases in this group.
Dr Lerut. We in fact had 30 as a mean.
My second question relates to the survival curves. You showed
that older age is doing worse, but that is probably because this is
a curve showing the overall survival. Wouldn’t it be better to show
disease-free survival,which is amore cancer-specific survival curve?
Dr Raja. Cancer-specific mortality is a soft end point, and can-
cer recurrence is similarly problematic. For these reasons, we use
all-cause mortality.
Dr Sebastien Gilbert (Ottawa, Ontario, Canada). Thank you
for your excellent presentation. I would like to know whetherThe Journal of Thoracic and Carendoscopic mucosal resection is routine in your evaluation of these
patients inasmuch as endoscopic ultrasound alone, even with the
highest resolution probe, has difficulty distinguishing between
mucosal and submucosal lesions. Second, in the case of intramu-
cosal esophageal cancer arising in the background of dysplastic
Barrett esophagus, is there an acceptable threshold in the probabil-
ity of lymph node metastases below which you may consider en-
doscopic resection and ablation with close follow-up, and
beyond which you would recommend esophageal resection?
Dr Raja.We do not routinely use endomucosal resection in pa-
tients with submucosal cancer. Endomucosal resection is used to
differentiate between deep intramucosal and superficial submuco-
sal invasion. Because of the unacceptable prevalence of regional
lymph node metastases in any patient with submucosal cancer,
we recommend that they undergo an esophagectomy.
Dr Stephen Cassivi (Rochester, Minn). I will make 2 points.
One is to congratulate your group again for parsing out the esoph-
ageal wall in a way that we have not seen before. You have taken an
area that is 500 to 1000 mm in depth and given us a lot of
information.
Second, I would like to emphasize, and maybe you can con-
firm this, that there is 10% lymphovascular invasion in just the
superficial part of the submucosa and an 8% lymph node metas-
tases. The true divide, from a therapeutic standpoint, is there-
fore at the muscularis mucosa. In terms of minimally invasive
or endoscopic treatments versus a surgical treatment, I think
that lymph node metastases rate is too high to allow for ade-
quate treatment from an endoscopic standpoint. Would you
agree?
Dr Raja. Undeniably, submucosal cancers have an exponen-
tially increasing prevalence of regional lymph node metastases
with increasing depth of invasion. Alarmingly, 8% of inner submu-
cosal cancers have regional lymph node metastasis. We agree that
the muscularis mucosa is an important divide for therapy.diovascular Surgery c Volume 142, Number 6 1411
TABLE E1. Cancer characteristics by pathologic diagnosis and depth of invasion
Variable/response
Adenocarcinoma* Squamous cell carcinoma*
Inner (n ¼ 35) Middle (n ¼ 26) Deep (n ¼ 46) P Inner (n ¼ 5) Middley (n ¼ 3) Deep (n ¼ 5) P
Greatest cancer length (cm)z 0/1.0/2.5 0.6/1.8/3.2 1.4/2.5/4.0 <.001 1.2/2.0/4.5 1.0, 2.0, 2.8 1.8/2.2/5.5 .8
Greatest cancer width (cm)z 0.5/1.3 0.1/1.3/2.0 0.7/1.5/3.0 <.001 0.5/1.0/2.7 0.5, 1.0, 1.0 1.0/1.6/4.0 .2
Cancer area (cm2)z 0/0.4/2.5 0/2.2/6.0 1.0/3.2/12 <.001 1.2/1.4/12 0.5, 2.0, 2.8 1.8/3.5/22 .2
Histologic grade .2 .02
G1 3 (8.6) 4 (15) 7 (15) 2 (40) 0 (0) 0 (0)
G2 21 (60) 14 (54) 15 (33) 3 (60) 2 (67) 2 (40)
G3 11 (31) 8 (31) 24 (52) 0 (0) 1 (33) 3 (60)
Lymphovascular invasion 2 (5.7) 5 (19) 15 (33) .003 2 (40) 0 (0) 2 (40) 1.0
No. of positive lymph nodes <.001 .03
0 32 (91) 23 (88) 26 (57) 5 (100) 3 (100) 2 (40)
1 3 (8.6) 1 (3.8) 14 (30) 0 (0) 0 (0) 2 (40)
2 0 (0) 0 (0) 3 (6.5) 0 (0) 0 (0) 1 (20)
3 0 (0) 0 (0) 2 (4.3) 0 (0) 0 (0) 0 (0)
4 0 (0) 0 (0) 1 (2.2) 0 (0) 0 (0) 0 (0)
5 0 (0) 2 (7.7) 0 (0) 0 (0) 0 (0) 0 (0)
Pathologic classification <.001 .03
pN0 32 (41) 23 (88) 26 (57) 5 (100) 3 (100) 2 (40)
pN1 3 (8.6) 1 (3.8) 17 (37) 0 (0) 0 (0) 3 (60)
pN2 0 (0) 2 (7.7) 3 (6.5) 0 (0) 0 (0) 0 (0)
Extracapsular lymph node
involvement
0/3 0/3 4/20 .3 — — 1/1x —
Total No. of lymph nodes
sampled
4/11/21 5/18/32 5/15/32 .04 0/8/22 6, 6, 8 5/21/29 .2
Surgical approach:
thoracotomy
18 (51) 15 (58) 31 (67) .1 2 (40) 3 (100) 5 (100) .02
*No. (%) or 15th/50th/85th percentiles. yActual values in 3 patients. zInner, n ¼ 34; middle, n ¼ 25; deep, n ¼ 45. xData available on 1/1, not all 3.
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